Will Novavax's vaccine be the fifth authorized on the Old Continent?
The European Medicines Agency (EMA) started examining the US biotech dossier on November 17 and could decide "
within a few weeks
Also awaiting a European green light, the Franco-Austrian biotech Valneva.
Covid-19: what Macron could announce to stem the fifth wave
Novavax's vaccine, called Nuvaxovid in Europe (Covovax in southern countries), has demonstrated an overall efficacy of 90% against Covid-19 at the end of its phase 3 clinical trials. Other studies are underway to assess the effectiveness of the vaccine as a booster dose, including a phase 2 trial in the United States and Australia.
The good results of this study strengthen our confidence in the potential of a booster dose of the NVX-CoV2373 vaccine to provide broad protection against the disease, including against known and emerging variants
," said Gregory M. Glenn, Director of R&D at Novavax.
Unlike messenger RNA vaccines (Pfizer / BioNTech,
This article is for subscribers only.
You have 77% left to discover.
Pushing back the limits of science is also freedom.
Continue reading your article for € 1 the first month
I ENJOY IT